Elanco Animal Health Inc

Elanco Animal Health Inc(ELAN)股票分析

$24.680

+0.795 (+3.22%)收盘时

Loading chart…
High
24.920
Open
23.970
VWAP
24.49
Vol
6.74M
Mkt Cap
7.05B
Low
23.870
Amount
165.10M
EV/EBITDA, TTM
13.23

Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.

AI analysis of Elanco Animal Health Inc (ELAN)

buy

Elanco Animal Health Inc is a good buy right now, with a current price of $24.11 and a forward P/E ratio of 22.779. The company has shown strong revenue growth, with Q2 2026 revenue increasing by 10% year-over-year, and a gross margin of 48.17% in the same quarter. The main risk is the negative net income reported in Q4 2025, which was -276 million USD, indicating potential volatility in earnings.

Analyst Ratings (11)

+3.32% upside
Hold
5 Buy
6 Hold
0 Sell
Current: 24.68
最低
22.00
平均
25.50
最高
30.00

KeyBanc

2026-08-06

目标价

$30

Overweight

Citi

2026-08-06

目标价

$34

Buy

Morgan Stanley

2026-07-22

目标价

$26

Equal Weight

TD Cowen

2026-06-18

目标价

$32

Buy

Morgan Stanley

2026-05-15

目标价

$23

Equal Weight

估值指标

The current forward P/E ratio for Elanco Animal Health Inc (ELAN) is 21.74, compared to its 5-year average forward P/E of 17.99.

Forward P/E

Fair
5Y Average P/E
17.99
Current P/E
21.74
高估
22.70
低估
13.28

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
13.80
Current EV/EBITDA
13.23
高估
16.76
低估
10.84

Forward P/S

Fair
5Y Average P/S
1.83
Current P/S
2.21
高估
2.43
低估
1.22

Alphio AI Price Scenarios for ELAN

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ELAN

$13.97

情景价格

B

Base

Base · 50%ELAN

$13.55

情景价格

B

Bear

Bear · 25%ELAN

$10.58

情景价格

Whales holding ELAN

B

Blackhill Capital, Inc

+ HoldingELAN

+7.85%

3M Return

D

Douglas Lane & Associates, LLC

+ HoldingELAN

+5.50%

3M Return

B

Bowen, Hanes & Company, Inc.

+ HoldingELAN

+1.84%

3M Return

事件时间线

2026-08-26 (ET)

09:00:00

Elanco Animal Health Completes 25,000-SF Manufacturing Expansion

2026-08-07 (ET)

15:00:00

Elanco Receives FDA Emergency Authorization for CLiK Extra to Prevent New World Screwworm Infestations

2026-08-05 (ET)

07:00:00

Elanco Reports Q2 Revenue of $1.37B, Beating Consensus

07:00:00

Elanco Animal Health Raises FY26 Revenue Outlook to $5.09B-$5.14B

2026-06-18 (ET)

07:30:00

Elanco Animal Health Establishes Elanco Ventures Investment Platform with $25M Commitment

资讯

ELAN FAQ — answered by Alphio AI

Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Elanco Animal Health Inc is a good buy right now, with a current price of $24.11 and a forward P/E ratio of 22.779. The company has shown strong revenue growth, with Q2 2026 revenue increasing by 10% year-over-year, and a gross margin of 48.17% in the same quarter. The main risk is the negative net income reported in Q4 2025, which was -276 million USD, indicating potential volatility in earnings.

11 analysts cover ELAN: 5 rate it Buy, 6 Hold and 0 Sell. The average price target is 25.50.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始